Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study

Clinical studies treating pediatric and adult solid tumors, such as glioblastoma (GBM), with a triple-drug regimen of temozolomide (TMZ), bevacizumab (BEV), and irinotecan (IRI) [TBI] have demonstrated various efficacies, but with no unexpected toxicities. The TBI regimen has never been studied in r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Guangrong, Rao, Mayank, Zhu, Ping, Liang, Buqing, El-Nazer, Rasheda T., Fonkem, Ekokobe, Bhattacharjee, Meenakshi B., Zhu, Jay-Jiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366009/
https://www.ncbi.nlm.nih.gov/pubmed/30766509
http://dx.doi.org/10.3389/fneur.2019.00042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366009/
https://www.ncbi.nlm.nih.gov/pubmed/30766509
http://dx.doi.org/10.3389/fneur.2019.00042

Ejemplares similares